{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Graham RLJ"],"funding":["Medical Research Council","Mastocytosis Charity"],"pagination":["5087"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8948255"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["Mastocytosis is a rare myeloproliferative disease, characterised by accumulation of neoplastic mast cells in one or several organs. It presents as cutaneous or systemic. Patients with advanced systemic mastocytosis have a median survival of 3.5 years. The aetiology of mastocytosis is poorly understood, patients present with a broad spectrum of varying clinical symptoms that lack specificity to point clearly to a definitive diagnosis. Discovery of novel blood borne biomarkers would provide a tractable method for rapid identification of mastocytosis and its sub-types. Moving towards this goal, we carried out a clinical biomarker study on blood from twenty individuals (systemic mastocytosis: n = 12, controls: n = 8), which were subjected to global proteome investigation using the novel techno"],"journal":["Scientific reports"],"pubmed_title":["SWATH-MS identification of CXCL7, LBP, TGFβ1 and PDGFRβ as novel biomarkers in human systemic mastocytosis."],"pmcid":["PMC8948255"],"funding_grant_id":["MR/P016502/1"],"pubmed_authors":["Myers B","McMullen AA","Graham C","Graham RLJ","Dempsey-Hibbert NC","Moore G"],"additional_accession":[]},"is_claimable":false,"name":"SWATH-MS identification of CXCL7, LBP, TGFβ1 and PDGFRβ as novel biomarkers in human systemic mastocytosis.","description":"Mastocytosis is a rare myeloproliferative disease, characterised by accumulation of neoplastic mast cells in one or several organs. It presents as cutaneous or systemic. Patients with advanced systemic mastocytosis have a median survival of 3.5 years. The aetiology of mastocytosis is poorly understood, patients present with a broad spectrum of varying clinical symptoms that lack specificity to point clearly to a definitive diagnosis. Discovery of novel blood borne biomarkers would provide a tractable method for rapid identification of mastocytosis and its sub-types. Moving towards this goal, we carried out a clinical biomarker study on blood from twenty individuals (systemic mastocytosis: n = 12, controls: n = 8), which were subjected to global proteome investigation using the novel techno","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-05-18T12:06:53.913Z","creation":"2025-05-18T12:06:53.913Z"},"accession":"S-EPMC8948255","cross_references":{"pubmed":["35332176"],"doi":["10.1038/s41598-022-08345-3"]}}